Drug intelligence / Profile preview

AKTX-103

Development stage: Preclinical
Lead developer: Akari Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

AKTX-103 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Akari Therapeutics. The program was integrated into Akari's pipeline following its 2024 merger with Peak Bio, which provided access to a proprietary ADC platform featuring the PH-1 payload (a thailanstatin A derivative that acts as a spliceosome inhibitor). While the specific molecular target and primary therapeutic indications for AKTX-103 remain undisclosed as of early 2025, the asset represents a key component of Akari's strategic expansion into oncology and inflammatory disease treatments leveraging multi-modal platforms.

Targets

Neuraminidase

Beyond the preview

Go deeper on AKTX-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKTX-103.

Explore the full profile